Patents Issued in January 28, 2014
  • Patent number: 8637443
    Abstract: The invention provides solvent and cleaning compositions comprising an ionic surfactant, which preferably has a fluorinated portion thereof, and a solvent selected from hydrofluoro- and/or hydrochlorofluoro-olefins. Additionally, the invention provides drying, dry cleaning, and soil repellency compositions containing a hydrofluoro- or hydrochlorofluoro-olefin and said surfactant. Additionally, the invention provides drying compositions containing a hydrofluoro-olefin or hydrochlorofluoro-olefin and an alcohol such as methanol, ethanol or isopropanol.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: January 28, 2014
    Assignee: Honeywell International Inc.
    Inventors: Rajat Basu, Gary Zyhowski, Kane Cook, David Nalewajek
  • Patent number: 8637444
    Abstract: A method of delivering a material to a person comprising applying an anhydrous composition to a person, wherein the anhydrous composition comprises a base and metal organic framework formed from a recyclable porous material with the material adsorbed into the metal organic framework, and the recyclable porous material has a structure that breaks down when contacted with water to release the material. An anhydrous composition comprising a base and a metal organic framework formed from a recyclable porous material with the material adsorbed into the metal organic framework, wherein the recyclable porous material has a structure that breaks down when contacted with water to release the material.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: January 28, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Long Pan, Claudio Ortiz, Allen Puchalski
  • Patent number: 8637445
    Abstract: The invention provides a benefit agent delivery particle comprising hydroxylpropyl cellulose. The benefit agent delivery particle may further comprise a non-polysaccharide polymer, preferably an aminoplast polymer. The benefit agent delivery particle may comprise a perfume. The invention also provides a process for the manufacture of the particles in which perfume oil is encapsulated using emulsion polymerization to form core-shell particles, (in the alternative the perfume may be adsorbed later) and, a further polymer layer is formed on the outer surface of the core shell-particles in the presence of the delivery aid.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: January 28, 2014
    Assignee: Conopco Inc.
    Inventors: Honggang Chen, Paul Ferguson, Christopher Clarkson Jones, David Richard Arthur Mealing, Xiaoyun Pan, Jinfang Wang
  • Patent number: 8637446
    Abstract: Perfume compositions having functional perfume components for aiding in perfume evaporation. The functional perfume components have a Kovat's index in the range of 900-1400 and an ODT of greater than about 1 ppb. In one embodiment, the functional perfume component may be present in an amount from at least about 10% by weight of the composition. In another embodiment, the composition containing a function perfume component is substantially free of a VOC.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: January 28, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Steven Louis Diersing, Ricky Ah-Man Woo, Rhonda Jean Jackson, Zaiyou Liu, Ronald David Turner, Fernando Ray Tollens, La Var Duran Derrick
  • Patent number: 8637447
    Abstract: The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's) comprising the same, as the active ingredient in compositions for the treatment of pathologic disorders, preferably disorders associated with inactivation of cellular proteins involved with quality control processes, particularly, chaperones. The invention further provides methods for the treatment of such disorders and the use of the SV40 capsid proteins for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: January 28, 2014
    Assignee: Gene Vector Technologies (GVT)
    Inventor: Ariella Oppenheim
  • Patent number: 8637448
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: January 28, 2014
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Patent number: 8637449
    Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
  • Patent number: 8637450
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Patent number: 8637451
    Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Synergy Pharmaceuticals Inc.
    Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
  • Patent number: 8637452
    Abstract: The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: January 28, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Shuguang Zhang, Alexander Rich, Karolina Corin, Lotta T. Tegler
  • Patent number: 8637453
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: January 28, 2014
    Assignees: St George's Hospital Medical School, The University of Manchester
    Inventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Key, Meriel Ruth Major, Mark Richard Stewart
  • Patent number: 8637454
    Abstract: Methods, kits and compositions are disclosed that include an isolated kallikrein inhibitor for the treatment of mucositis.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: January 28, 2014
    Assignee: Dyax Corp.
    Inventor: Andrew Sternlicht
  • Patent number: 8637455
    Abstract: The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: January 28, 2014
    Assignees: Affinergy, LLC, DePuy Synthes Products, LLC
    Inventors: Martyn K. Darby, Isaac G. Sanford, R. Edward Benson, Hanne Gron, Paul T. Hamilton, Shrikumar A. Nair, Doug Buechter, Elliott Gruskin
  • Patent number: 8637456
    Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: January 28, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Karthik Viswanathan, Venkataramanan Soundararajan, S. Raguram, Viswanathan Sasisekharan, Vidya Subramanian
  • Patent number: 8637457
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: January 28, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Valdas Jurkauskas
  • Patent number: 8637458
    Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: January 28, 2014
    Assignee: Biodel Inc.
    Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
  • Patent number: 8637459
    Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: January 28, 2014
    Assignee: Emory University
    Inventor: Shanthi Srinivasan
  • Patent number: 8637460
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: January 28, 2014
    Assignee: HDL Therapeutics LLC
    Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Patent number: 8637461
    Abstract: The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: January 28, 2014
    Assignee: Kuwait University
    Inventors: Fahd Al-Mulla, Milad Bitar
  • Patent number: 8637462
    Abstract: This document relates to methods and materials for treating diseases or disorders associated with elevated platelet counts (e.g., essential thrombocythemia, secondary thrombocytosis, congenital amegakaryocytic thrombocytopenia, sepsis, or asplenism) as well as methods and materials for treating diseases or disorders associated with elevated platelet adhesion to collagen (e.g., acute coronary syndromes, angina pectoris, chronic atherosclerosis, diabetes, or hypertension).
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 28, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Robert D. Simari, Sinny Delacroix
  • Patent number: 8637463
    Abstract: The invention provides a peptide having an activity of inhibiting angiotensin-converting enzyme (ACE), and a food and drink and/or a pharmaceutical composition containing the peptide.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: January 28, 2014
    Assignee: Meiji Dairies Corporation
    Inventors: Hidekazu Tonouchi, Masayuki Suzuki, Masayuki Uchida, Munehiro Oda
  • Patent number: 8637464
    Abstract: The present invention provides a method to identify a test compounds capability to modulate p75.sup.NTR induced apoptosis, said method comprising: i. Transfecting a suspension of eukaryotic cells with a vector encoding SEQ ID No.4 OR SEQ ID No.6), ii. Contacting said cells with the compound to be tested, and iii. Determine the apoptotic response in said cells, wherein an alteration in apoptotic response in the presence of said test compound compared to the apoptotic response in the absence of the test compound is an indication of the ability of the test compound to modulate p75.sup.NTR induced apoptosis.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: January 28, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Wouter David Bruinzeel, Miroslav Cik
  • Patent number: 8637465
    Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: January 28, 2014
    Assignee: Kobenhavns Universitet
    Inventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
  • Patent number: 8637466
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: January 28, 2014
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Patent number: 8637467
    Abstract: Provided is the composition of a peptide and its mutagenic version, or other derivatives with the same 3-D structure with activity to bind the extracellular domain of PDGFR-?, or -?, but does not dimerize by itself, wherein said peptide comprises the sequence shown as SEQ ID NO: 1, 2 or 3. Also provided is the composition of the nucleotide sequence encoding said peptide and its derivatives, and the usage of said peptide and derivatives of the peptide in preparation of medicine for the prevention and treatment of fibrosis diseases, such as liver, kidney, and lung fibrosis, primary cancer, and cancer metastasis, especially stomach cancer, liver cancer, breast cancer, and lung cancer.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: January 28, 2014
    Assignee: Wuxi MTLH Biotechnology Co., Ltd.
    Inventors: Lan Huang, Hua Zhou, Shengtao Yuan
  • Patent number: 8637468
    Abstract: Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: January 28, 2014
    Assignee: The University of Kansas
    Inventor: Blake R. Peterson
  • Patent number: 8637469
    Abstract: The invention describes a method of treating upper airway disease by administering a composition of one or more proinflammatory cytokine inhibitors sufficient to inhibit inflammation in the upper airways. The proinflammatory cytokines that are inhibited include TNF, IL-1 and IL-8. A medication dispensing unit which includes a container and a delivery system is used to administer the composition. The delivery system further encompasses a one-way valve, a microcatheter, or a liquid-pressure type sprayer.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: January 28, 2014
    Inventor: Roy Clifford Levitt
  • Patent number: 8637470
    Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: January 28, 2014
    Assignee: The Regents of the University of California
    Inventors: Pinchas Cohen, Laura J. Cobb
  • Patent number: 8637471
    Abstract: The outcome of an in vitro fertilization (IVF) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (HRG) gene or protein analysis of HRG. The proline isoform of HRG or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: January 28, 2014
    Assignee: Karolinska Institutet Innovations AB
    Inventors: Karin Karehed, Helena Akerud
  • Patent number: 8637472
    Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: January 28, 2014
    Assignees: University of Washington Through Its Center for Commercialization, Florida Gulf Coast University
    Inventors: Scott F. Michael, Sharon Isern, Joshua Costin, Vaikuntanath Samudrala, Ekachai Jenwitheesuk
  • Patent number: 8637473
    Abstract: Synthetic molecule construct of the structure F—S1—S2-L where F is an O-linked mono-, di-, tri- or oligo-saccharide, S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl, S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—, and L is a diacyl- or dialkyl-glycerophospholipid.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: January 28, 2014
    Assignee: Kode Biotech Limited
    Inventors: Nicolai Bovin, Lissa Gilliver, Stephen Henry, Elena Korchagina
  • Patent number: 8637474
    Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: January 28, 2014
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
  • Patent number: 8637475
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: January 28, 2014
    Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, The Centre National de la Recherché Scientifique, L'Universite Montpelier II
    Inventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
  • Patent number: 8637476
    Abstract: Mammalian host cells for use in a cell-mediated tranfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of downregulating a chosen target gene. Living cells expressing the target gene are then exposed to the ACs. The ACs are processed by the living cells, and the RNAi molecule in the ACs downregulates the expression of the target gene in living cells.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: January 28, 2014
    Assignee: Loma Linda University
    Inventors: Fengchun Li, Alan P. Escher
  • Patent number: 8637477
    Abstract: Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: January 28, 2014
    Assignee: Akshaya Bio Inc.
    Inventors: Rajan George, Bruce D. Hirsche
  • Patent number: 8637478
    Abstract: The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: January 28, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: C. Frank Bennett
  • Patent number: 8637479
    Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: January 28, 2014
    Assignee: Index Pharmaceuticals AB
    Inventors: Lisa C. Bandholtz, Alexander Gielen, Arezou Zargari, Oliver Von Stein, Lars-Göran Axelsson
  • Patent number: 8637480
    Abstract: It is an object of the present invention to provide a novel mitochondrial function-improving agent and a novel PGC-1? expression inducing agent. The present invention provides a mitochondrial function-improving agent and a PGC-1? expression inducing agent each of which comprises a lysine-specific demethylase-1 (LSD-1) inhibitor.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: January 28, 2014
    Assignee: National University Corporation Kumamoto University
    Inventors: Mitsuyoshi Nakao, Shinjiro Hino
  • Patent number: 8637481
    Abstract: There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: January 28, 2014
    Assignee: University Health Network
    Inventors: Fei-Fei Liu, Emma Ito, Inki Kim
  • Patent number: 8637482
    Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: January 28, 2014
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
  • Patent number: 8637483
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: January 28, 2014
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • Patent number: 8637484
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 28, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Patent number: 8637485
    Abstract: The crystal structure of the complex of S-adenosylmethionine methyl ester with h?doMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5?-deoxy-5?-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5?-deoxy-5?-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 28, 2014
    Assignees: Southern Research Institute, Cornell University, H. Lee Moffitt Cancer and Research Institute, The Penn State Research Foundation
    Inventors: John A. Secrist, III, Steven Ealick, Shridhar Bale, Anthony E. Pegg, Diane E. McCloskey, Wayne C. Guida
  • Patent number: 8637486
    Abstract: Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used as nutrients or in other medicinal application methods, can alter the DNA methylation pattern in a simple way through the well-understood mechanism of kinetic isotope effect (KIE). This effect could also be useful for modifying methylation kinetics in stem cell technology, cloning and as disease therapeutics.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: January 28, 2014
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 8637487
    Abstract: Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: January 28, 2014
    Inventors: Hubertus Josephus Maria Van De Heijning, Houkje Bouritius, Katrien Maria Jozefa Van Laere, Robert Johan Joseph Hageman
  • Patent number: 8637488
    Abstract: This invention relates to an extract obtained from a plant of the genus Odontoglossum of the family Orchidaceae, or from a plant derived from a hybrid plant of the genus Odontoglossum and the genus Cochlioda, to a method for preparing the extract, and to an external agent for skin comprising the extract.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: January 28, 2014
    Assignee: Nichirei Biosciences, Inc.
    Inventors: Akiko Sasaki, Masakazu Kawaguchi, Ayaka Himono
  • Patent number: 8637489
    Abstract: The present invention relates to a composition comprising: (a) at least one alkoxylated silicone acid; (b) at least one amino compound chosen from polyamines, alkoxylated polyamines, alkyl monoamines, alkoxylated monoamines and mixtures thereof; (c) at least one lipophilic compound; and (d) at least one solvent comprising water. Such a composition is clear in appearance, and stable. The present invention also relates to a method of making such a clear composition, and to a method of cosmetic treatment of a keratinous substrate using such a composition.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: January 28, 2014
    Assignee: L'Oreal
    Inventors: Nghi Van Nguyen, Sawa Hashimoto, David W. Cannell
  • Patent number: 8637490
    Abstract: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.
    Type: Grant
    Filed: July 1, 2012
    Date of Patent: January 28, 2014
    Assignee: UWM Research Foundation, Inc.
    Inventors: Xiaohua Peng, Yunyan Kuang, Sheng Cao, Wenbing Chen, Yibin Wang
  • Patent number: 8637491
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • Patent number: 8637492
    Abstract: Novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on a dendrimeric scaffold having a tri-functional core. The tri-functional core is a phosphorodiamidate or phosphoramide moiety.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: January 28, 2014
    Assignee: Gene Tools, LLC
    Inventor: Yong-Fu Li